Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?

BACKGROUND: PD-1/PD-L1 inhibitors are promising approaches for advanced Merkel cell carcinoma (MCC). Nevertheless, these inhibitors bear a high risk for induction of immune-related adverse events (irAEs), particularly flares of preexisting autoimmune diseases. Neurological irAEs of PD-1/PD-L1 inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaremba, Anne, Chorti, Eleftheria, Jockenhöfer, Finja, Bolz, Saskia, Sirin, Selma, Glas, Martin, Becker, Jürgen C., Ugurel, Selma, Roesch, Alexander, Schadendorf, Dirk, Livingstone, Elisabeth, Hagenacker, Tim, Zimmer, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541996/
https://www.ncbi.nlm.nih.gov/pubmed/31142383
http://dx.doi.org/10.1186/s40425-019-0626-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541996/
https://www.ncbi.nlm.nih.gov/pubmed/31142383
http://dx.doi.org/10.1186/s40425-019-0626-9

Ejemplares similares